DK3768709T3 - Mikrochip-kapillærelektroforese-assays og reagenser - Google Patents

Mikrochip-kapillærelektroforese-assays og reagenser Download PDF

Info

Publication number
DK3768709T3
DK3768709T3 DK19714055.1T DK19714055T DK3768709T3 DK 3768709 T3 DK3768709 T3 DK 3768709T3 DK 19714055 T DK19714055 T DK 19714055T DK 3768709 T3 DK3768709 T3 DK 3768709T3
Authority
DK
Denmark
Prior art keywords
reagents
capillary electrophoresis
electrophoresis assays
microchip capillary
microchip
Prior art date
Application number
DK19714055.1T
Other languages
English (en)
Inventor
Timothy Riehlman
Gabriel Carreau
Jeffrey Schneiderheinze
Nicole M Nall
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3768709T3 publication Critical patent/DK3768709T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44743—Introducing samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK19714055.1T 2018-03-19 2019-03-15 Mikrochip-kapillærelektroforese-assays og reagenser DK3768709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644933P 2018-03-19 2018-03-19
PCT/US2019/022525 WO2019182901A1 (en) 2018-03-19 2019-03-15 Microchip capillary electrophoresis assays and reagents

Publications (1)

Publication Number Publication Date
DK3768709T3 true DK3768709T3 (da) 2024-01-29

Family

ID=65952203

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19714055.1T DK3768709T3 (da) 2018-03-19 2019-03-15 Mikrochip-kapillærelektroforese-assays og reagenser

Country Status (21)

Country Link
US (1) US11054389B2 (da)
EP (2) EP3768709B1 (da)
JP (4) JP7315565B2 (da)
KR (3) KR102722812B1 (da)
CN (2) CN111868085B (da)
AR (1) AR117402A1 (da)
AU (2) AU2019239633B2 (da)
BR (1) BR112020015291B1 (da)
CA (2) CA3089655C (da)
DK (1) DK3768709T3 (da)
EA (1) EA202092203A1 (da)
ES (1) ES2969882T3 (da)
FI (1) FI3768709T3 (da)
HU (1) HUE065344T2 (da)
IL (2) IL277264B2 (da)
MX (2) MX2020009696A (da)
MY (1) MY202358A (da)
PL (1) PL3768709T3 (da)
SG (1) SG11202007011YA (da)
TW (2) TWI779177B (da)
WO (1) WO2019182901A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
HUE065344T2 (hu) 2018-03-19 2024-05-28 Regeneron Pharma Mikrochip kapilláris elektroforézis assay-k és reagensek
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN115398236B (zh) * 2020-01-21 2024-06-11 瑞泽恩制药公司 用于糖基化的蛋白质的电泳的去糖基化方法
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
BR112023024984A2 (pt) * 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6210915B1 (en) * 1997-12-31 2001-04-03 University Of Texas Systems Telomerase extraction method
CN100359015C (zh) * 1998-05-18 2008-01-02 伦敦大学专科学院 多肽激素磷酸盐沉着因子
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
JP2003114216A (ja) 2001-10-05 2003-04-18 Advance Co Ltd 電気泳動装置
EP1572909A4 (en) 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
CA2493671A1 (en) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
DE10258150A1 (de) 2002-12-10 2004-07-08 Dyomics Gmbh Hydrophile Marker auf der Basis von Benzopyrylo-Polymethinen
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
ES2381551T3 (es) 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Marcadores de riesgo para enfermedad cardiovascular
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
EP1811902A2 (en) 2004-11-15 2007-08-01 (OSI) Eyetech, Inc. Marker for fenestrae
EP1801573A1 (en) 2005-12-21 2007-06-27 Boehringer Mannheim Gmbh Method and apparatus for parallel two-dimensional electrophoresis
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EA022609B1 (ru) 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии
CN101827946A (zh) 2007-05-18 2010-09-08 茵维特罗根公司 快速蛋白质标记和分析
MX2010000970A (es) 2007-07-31 2010-03-09 Regeneron Pharma Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2010052556A1 (en) 2008-11-06 2010-05-14 Glenmark Pharmaceuticals S.A. Treatment with anti-alpha2 integrin antibodies
KR20100053015A (ko) * 2008-11-12 2010-05-20 경희대학교 산학협력단 인간 골수성 백혈병 세포주에 세포사멸을 유도하는 나프타자린 유도체
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010078601A1 (en) 2009-01-05 2010-07-08 The Regents Of The University Of California High throughput biomolecule separation and analysis
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CN102648415A (zh) 2009-08-25 2012-08-22 生命技术公司 定量荧光蛋白标准品
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
DK2780368T3 (da) 2011-11-14 2018-02-05 Regeneron Pharma Sammensætninger og fremgangsmåder til øgning af muskelmasse og muskelstyrke ved specifik antagonisering af gdf8 og/eller activin a
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014055936A1 (en) * 2012-10-04 2014-04-10 Integenx Inc. Preservation of biological materials in non-aqueous fluid media
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
EP2968454B1 (en) 2013-03-15 2019-02-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
CN107001461A (zh) 2014-09-16 2017-08-01 瑞泽恩制药公司 抗胰高血糖素抗体及其使用方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
HUE065344T2 (hu) 2018-03-19 2024-05-28 Regeneron Pharma Mikrochip kapilláris elektroforézis assay-k és reagensek

Also Published As

Publication number Publication date
FI3768709T3 (fi) 2024-02-01
JP2023093664A (ja) 2023-07-04
KR102503356B1 (ko) 2023-02-24
EA202092203A1 (ru) 2020-12-07
BR112020015291A2 (pt) 2020-12-08
KR20200130821A (ko) 2020-11-20
EP4317959B1 (en) 2026-04-29
JP7486637B2 (ja) 2024-05-17
IL277264B1 (en) 2023-11-01
KR102777672B1 (ko) 2025-03-10
TWI779177B (zh) 2022-10-01
AU2026201984A1 (en) 2026-04-02
KR20240157124A (ko) 2024-10-31
IL277264B2 (en) 2024-03-01
CN111868085A (zh) 2020-10-30
TW202516175A (zh) 2025-04-16
US20190285580A1 (en) 2019-09-19
TW202323813A (zh) 2023-06-16
CA3246952A1 (en) 2025-10-31
JP2025156526A (ja) 2025-10-14
CN119335032A (zh) 2025-01-21
ES2969882T3 (es) 2024-05-23
IL277264A (en) 2020-10-29
CA3089655C (en) 2026-01-20
MY202358A (en) 2024-04-24
JP7724903B2 (ja) 2025-08-18
TW202004178A (zh) 2020-01-16
SG11202007011YA (en) 2020-08-28
KR102722812B1 (ko) 2024-10-29
AU2019239633A1 (en) 2020-11-19
TWI854343B (zh) 2024-09-01
WO2019182901A1 (en) 2019-09-26
CA3089655A1 (en) 2019-09-26
JP7315565B2 (ja) 2023-07-26
EP3768709A1 (en) 2021-01-27
IL307577B1 (en) 2025-02-01
HUE065344T2 (hu) 2024-05-28
AU2019239633B2 (en) 2025-12-18
AR117402A1 (es) 2021-08-04
EP4317959A3 (en) 2024-03-27
MX2020009696A (es) 2020-10-07
IL307577B2 (en) 2025-06-01
KR20230031987A (ko) 2023-03-07
IL307577A (en) 2023-12-01
CN111868085B (zh) 2024-11-05
BR112020015291B1 (pt) 2023-09-26
US11054389B2 (en) 2021-07-06
JP2021516334A (ja) 2021-07-01
EP3768709B1 (en) 2023-12-27
JP2024097873A (ja) 2024-07-19
PL3768709T3 (pl) 2024-05-20
EP4317959A2 (en) 2024-02-07
MX2024012221A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
DK3768709T3 (da) Mikrochip-kapillærelektroforese-assays og reagenser
IL283416A (en) Genomic infrastructure for on-site or cloud-based dna and rna processing and analysis
KR102349259B9 (ko) 친화성 시약을 이용한 핵산 시퀀싱
EP3698872A4 (en) MICROFLUIDIC DETECTION CHIP FOR MULTI-CHANNEL RAPID DETECTION
EP3885760A4 (en) MICROFLUIDIC CHIP
EP3884048A4 (en) DESIGN AND SELECTION OF AFFINITY REAGENTS
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
IL290274A (en) Methods and reagents for nucleic acid sequencing and associated applications
IL269779A (en) Methods and reagents for analyzing protein-protein interfaces
DK3746225T3 (da) Analytiske systemer og fremgangsmåder
EP4364850A4 (en) MICROFLUIDIC CHIP
IL280503A (en) Enhanced extended depth of focusing on biological samples
GB2578528B (en) Mixed-phase fluids for nucleic acid sequencing and other analytical assays
HUE048752T2 (hu) Mintabefogadó elem, analizálókészlet és eljárás egy folyadék, különösen egy hûtõ-kenõanyag emulzió elemzésére
EP3932552C0 (en) MICROFLUIDIC CHIP
EP4292712A4 (en) Microfluidic chip
EP3464598A4 (en) Aptamer-based analyte assays
EP3765197C0 (en) INTEGRATED PIPETTING DEVICE
DK3607065T5 (da) Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek
EP4159872C0 (en) DNA MARKING
DK3484623T3 (da) Dispenseringsapparat til flydende analytisk reagens og analytiske kit og anvendelsesfremgangsmåder relateret dertil
EP3857231C0 (en) QUANTIFICATION OF ANALYTES
DK3476942T3 (da) Lange kimlinje-dh-gener og antistoffer med lang hcdr3
EP3811083A4 (en) PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF
IL271237A (en) Image capillary isoelectric focusing to analyze protein variants in a sample matrix